{"id":3327,"date":"2003-12-01T00:00:00","date_gmt":"2003-12-01T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/index.php\/2003\/12\/01\/pmn211-article02\/"},"modified":"2019-02-18T17:51:29","modified_gmt":"2019-02-18T17:51:29","slug":"pmn211-article02","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmn211-article02\/","title":{"rendered":"Managing Privacy Risks in Your Commercial Practices"},"content":{"rendered":"

Managing Privacy Risks in Your Commercial Practices Advice from Two Pharma Attorneys
Even though the privacy regulations under HIPAA (the Health Insurance Portability and Accountability Act of 1996) do not directly apply to pharmaceutical companies, HIPAA may have heightened health privacy sensitivities among consumers and health professionals. Pharma sales reps, for example, have been denied access to physicians rightly or wrongly because of HIPAA. <\/p>\n

There are many pharmaceutical commercial activities that are impacted by privacy concerns and as many of these activities are fulfilled by vendors and partners, the industry needs to “get its arms around what vendors are doing,” according to Allison J. Gassaro, Senior Attorney, NA Legal at Aventis Pharmaceuticals. That means more vendor privacy policy due diligence and certification by pharma may be the norm and vendors should be prepared. <\/p>\n

Learn what practical advice two attorneys at pharmaceutical companies have for their colleagues wishing to manage privacy risks.<\/p>\n

Read this article now. It’s FREE…<\/b> <\/p>\n

Download PDF file<\/a><\/b><\/p>\n<\/p>\n

PMN211-02
Issue: Vol. 2, No. 10: December 2003<\/p>\n

Word Count: n\/a <\/p>\n Find other articles in related Topic Areas:<\/b> <\/p>\n